by The global Ornithine Transcarbamylase Deficiency Treatment Market is estimated to be valued at US$ 810.4 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Ornithine transcarbamylase deficiency (OTC deficiency) is an X-linked genetic disorder caused by mutations in the OTC gene that codes for the ornithine transcarbamylase enzyme. This enzyme helps remove excess nitrogen from the body during the break down of protein molecules. Due to a deficiency or absence of OTC, toxic levels of ammonia can accumulate in the blood leading to hyperammonemia. The major treatment options for OTC deficiency are drugs like, nitisinone, sodium phenylbutyrate, glycerol phenylbutyrate along with special protein restricted diets and ammonia scavengers. Recently, gene therapies have also emerged as a promising new treatment approach for this deficiency.
Market key trends:
The global ornithine transcarbamylase deficiency treatment market is expected to witness significant growth over the forecast period attributed to increasing research and development activities focused on developing novel and improved treatment options. Nitisinone, marketed as Orfadin by Swedish Orphan Biovitrum AB, is one of the major treatment option for ornithine transcarbamylase deficiency. Increasing global adoption of nitisinone over other drugs is expected to propel the market growth during the forecast period. Additionally, the recent approval and commercialization of newborn screening tests for early diagnosis of ornithine transcarbamylase deficiency is also anticipated to augment the market growth between 2023 and 2030.
Porter’s Analysis
Threat of new entrants: The ornithine transcarbamylase deficiency treatment market has moderately barriers for new players owing to high research and development costs associated with drug development.
Bargaining power of buyers: The bargaining power of buyers in the ornithine transcarbamylase deficiency treatment market is moderate as established key players offer innovative drugs for the treatment of rare genetic disorder.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitute raw materials and suppliers in the ornithine transcarbamylase deficiency treatment market.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options currently available for ornithine transcarbamylase deficiency.
Competitive rivalry: The competitive rivalry in ornithine transcarbamylase deficiency treatment market is high due to established pharmaceutical companies focusing on development of novel drugs for the treatment of rare genetic disorder.
Key Takeaways
The global Ornithine Transcarbamylase Deficiency Treatment Market Share is expected to witness high growth, exhibiting CAGR of 4.2% over the forecast period, due to increasing research and development investments by key players for development of innovative drugs.
Regional analysis
North America is expected to dominate the global ornithine transcarbamylase deficiency treatment market during the forecast period. This is primarily attributed to rising prevalence of genetic disorders, growing healthcare expenditure, and presence of established pharmaceutical companies in the region. Europe is expected to register steady growth in the market.
Key players
Key players operating in the ornithine transcarbamylase deficiency treatment market are Horizon Therapeutics Plc, Bausch Health Companies Inc., Danone, Nestlé, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc., Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., and Assertio Holdings, Inc. These players are focusing on new product launches and collaborations to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
